References

0

01

The GTN "Surveillance for Adverse Events Following Immunizations" training course has been held at: University of Cape Town in South Africa; National Pharmacovigilance Centre in Tunisia; Epidemiological Unit, Ministry of Health in Sri Lanka; and, Tarassevich Institute in Russia. For more information, see http://www.who.int/immunization_standards/vaccine_quality/gtn_aefi.

02

World Health Organization (WHO), United Nations Children's Fund (UNICEF), World Bank. State of the world's vaccines and immunization, 3rd ed, Geneva: WHO, 2009.

03

World Health Organization (WHO). "Progress in global measles control and mortality reduction, 2000–2007", Weekly Epidemiological Record, Geneva: WHO, 2008: 83(49):441–448.

04

Copenhagen Consensus 2008. Available at: http://www.copenhagenconsensus.com (Accessed 1 December 2009).

05

World Health Organization Immunization, Vaccines and Biologics (WHO/IVB) database. Database includes 193 WHO Member States. Data as of July 2009.

06

Plotkin SL, Plotkin SA. "A short history of vaccination," In: Plotkin S, Orenstein W, Offit PA. Vaccines, 5th edition, Philadelphia: Saunders, 2008.

07

Chen RT et al. "The Vaccine Adverse Event Reporting System (VAERS)," Vaccine, 1994: 12(6):542–550.

08

Wilson, CB, Marcuse, EK. "Vaccine safety – vaccine benefits: science and the public's perception," Nature Reviews Immunology, 2001: 1:160–165.

09

World Health Organization (WHO). Available at: http://www.who.int/vaccines/en/smallpox.shtml (Accessed 2 December 2009).

1

10

United Nations Children Fund (UNICEF). Available at: http://www.unicef.org (Accessed 2 December 2009).

11

Milstien, JB. "Regulation of vaccines: strengthening the science base," Journal Public Health Policy, 2004: 25(2):173–189.

12

Baylor NW, Midthun K. "Regulation and testing of vaccines," In: Plotkin S, Orenstein W, Offit PA. Vaccines, 5th edition, Philadelphia: Saunders, 2008.

13

Duclos P, Bentsi-Enchill AD, Pfeifer D. "Vaccine safety and adverse events: lessons learnt," In: Kaufmann SHE and Lamert PH. The Grand Challenge for the Future, Basel, Switzerland: 2005: 209–229.

14

Offit PA, David RL, Gust D. "Vaccine safety," In: Plotkin S, Orenstein W, Offit PA. Vaccines, 5th edition, Philadelphia: Saunders, 2008.

15

Malaria Vaccine Initiative, PATH. Fact Sheet: Clinical trials: Steps in malaria vaccine development, Seattle, Washington.

16

US Centers for Disease Control and Prevention (CDC). "Intussusception among recipients of rotavirus vaccine – United States, 1998–1999", Morbidity and Mortality Weekly Report, 1999: 48:577–581.

17
18

Ruiz-Palacios G, Pérez-Schael I, Velázquez F, et al. "Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis," New England Journal of Medicine, 2006: 354(1):11–22.

19

Vesikari T, Matson D, Dennehy P, et al. "Safety and efficacy of a pentavalent human-bovine (wc3) reassortant rotavirus vaccine," New England Journal of Medicine, 2006: 354(1):23–33.

2

20

Chen RT, Glasser J, Rhodes P et al. "Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States," Pediatrics, 1997: 99(6):765–773.

21

US Centers for Disease Control and Prevention. Website (Clinical Immunization Safety Assessment Network section) http://www.cdc.gov/vaccinesafety/Activities/CISA.html (Accessed 23 February 2010).

22

US Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices, February 21–22, 2007, Record of the Proceedings, Atlanta, Georgia: 2007.

23

US Centers for Disease Control and Prevention (CDC). "Prevention of rotavirus gastroenteritis among infants and children; recommendations of the Advisory Committee on Immunization Practices", Morbidity and Mortality Weekly Report, 2006: 55(RR-12).

24

Duclos P. "A global perspective on vaccine safety," Vaccine, 2004: 22:2059–2063.

25

European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use. CHMP Recommendations for the Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing Authorisation Application for a Pandemic Influenza Vaccine, EMEA/32706/2007: London, 19 January 2007.

26

Infant mortality and births from 2008 Immunization summary, WHO/UNICEF (The 2010 edition).

27

Uppsala Monitoring Centre. Available at: www.who-umc.org (Accessed 24 February 2010).

28

World Health Organization (WHO). "BCG vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2004:79(4):25–40.

29

World Health Organization (WHO). "Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries", Weekly Epidemiological Record, Geneva: 2003:78(28):241–252.

3

30

World Health Organization (WHO). "Pertussis vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2005:80(4):29–40.

31

World Health Organization (WHO). "Measles vaccines: WHO position paper", Weekly Epidemiological Record, Geneva: 2009:84(35):349–360.

32
33

World Health Organization (WHO). "Module 4: Ensuring safe injections" In: Immunization in Practice, WHO/IVB/04.06, Geneva: WHO, 2004.

34

Black S, Eskola J, Siegrist C et al. "Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines," Lancet, Published Online October 21, 2009. DOI:10.1016/S0140- 6736(09)61877–8.

35

World Health Organization (WHO). "Causality assessment of adverse events following immunization", Weekly Epidemiological Record, Geneva: WHO, 2001: 76(12):85–89.

36

World Health Organization (WHO). Aide Mémoire: Adverse Events Following Immunization (AEFI): Causality Assessment, WHO/IVB, Geneva: 2005.

37

World Health Organization Western Pacific Regional Office (WHO/WPRO), PATH. Third Biregional Meeting on Control of Japanese Encephalitis, Manila: WHO, 2007.

38

World Health Organization (WHO). "Global Advisory Committee on Vaccine Safety: Safety of Japanese encephalitis vaccination in India", Weekly Epidemiological Record, Geneva: WHO, 2007: 82(3):23–24.

39

Global Advisory Committee on Vaccine Safety (GACVS) and World Health Organization Secretariat. "Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS", Expert Review Vaccines, 2009:8(6) 705–716.

4

40

The Brighton Collaboration. Available at: http://www.brightoncollaboration.org (accessed 18 November 2009).

41

World Health Organization (WHO). Available at: www.who.int/immunization_standards/vaccine_quality/gtn_index (Accessed 18 March 2010).

42

The Uppsala Monitoring Centre. Available at: www.who-umc.org (accessed 18 November 2009).

43

Folb, PI, Bernatowska, W, Chen R, et al. "A Global Perspective on Vaccine Safety and Public Health: The Global Advisory Committee on Vaccine Safety", American Journal of Public Health, November 2004: 94(11):1926–1931.

44

World Health Organization (WHO). "Global Advisory Committee on Vaccine Safety, report of meeting held 17–18 June 2009", Weekly Epidemiological Record, Geneva: 2009: 84(40):330–332.

45

World Health Organization (WHO). Available at: www.who.int/immunization_safety/safety_quality/vaccine_safety_websites (Accessed 18 March 2010).

46

World Health Organization (WHO). The Importance of Pharmacovigilance: safety monitoring of medicinal products, Geneva: WHO, 2002.

47

WHO (2012). WHO vaccine reaction rates information sheets. www.who.int/vaccine_safety/initiative/tools/vaccinfosheets.

48

Uppsala Monitoring Centre (UMC). Available at: www.who-umc.org (Accessed 18 November 2009).

49

Council for International Organizations of Medical Sciences/World Health Organization (CIOMS/WHO) Working Group on Vaccine Pharmacovigilance. Vaccine Pharmacovigilance Definition. Available at: www.cioms.ch (Accessed 10 February 2010).

5

50

Global Advisory Committee on Vaccine Safety (GACVS) and World Health Organization Secretariat. "Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS," Expert Review Vaccines, 2009: 8(6),705–716.

51

Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M and the VAERS Working Group. "Intussusception Among Recipients of Rotavirus Vaccine: Reports to the Vaccine Adverse Event Reporting System" Pediatrics, 2001: 107;e97 DOI:10.1542/peds.107.6.e97.

52

Robert Pless, Public Health Agency of Canada. (Personal communication January 2010).

53

World Health Organization (WHO). Available at: www.who.int/immunization_standards/national_regulatory_authorities/strengthening (Accessed 1 March 2009).

54

Burgess DC, Burgess MA, Leask J. The MMR vaccination and autism controversy in United Kingdom 1998–2005: inevitable community outrage or a failure of risk communication? Vaccine 24, 3912–3928 (2006).

55

World Health Organizaton Global Training Network. "Similarities and differences between vaccines and medicines," In: WHO Global Training Network: Adverse events following immunization (AEFI), Geneva: WHO, 2009.

56

World Health Organization (WHO). "Module 3: The cold chain" In: Immunization in Practice, Geneva: WHO/IVB/04/06, 2004.

57

World Health Organization (WHO). "Module 4: Ensuring safe injections" In: Immunization in Practice, Geneva: WHO/IVB/04/06, 2004.

58

World Health Organization (WHO). "Module 6: Holding an immunization session" In: Immunization in Practice, Geneva: WHO/IVB/04/06, 2004.

59

Gold R. Your Child's Best Shot: A parent's guide to vaccination 3rd edition, Canadian Paediatric Society, Canada, 2006.

6

60

Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical Safety Information on Drugs – Report of CIOMS Working Group III, Geneva: WHO, 1995.

61

World Health Organization (WHO). "Rotavirus vaccines: an update" Weekly Epidemiological Record, Geneva: 2009:84(51–52):533–538.

62

World Health Organization (WHO). "Yellow fever vaccine: WHO position paper" Weekly Epidemiological Record, Geneva: 2003:78(40):349–360.

63

World Health Organization (WHO). "Hepatitis B vaccines: WHO position paper", Weekly Epidemiological Record, Geneva: 2009:84(40):405–420.

64
65

World Health Organization (WHO). "WHO position paper on Haemophilus influenzae type b conjugate vaccines", Weekly Epidemiological Record, Geneva: 2006:81(47):445—452.

66

World Health Organization (WHO). "Pneumococcal conjugate vaccine for childhood immunization – WHO position paper", Weekly Epidemiological Record, Geneva: 2007:82(12):93–104.

67

Meningitis vaccine project. Available at: www.meningvax.org (Accessed 1 January 2010).

68

World Health Organization (WHO). "Tetanus vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2006:81(20):197–208.

69

World Health Organization (WHO). "Diphtheria vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2006:81(3):21–32.

7

70

Adapted from Martin Friede.

71
72

World Health Organization (WHO). "Revised BCG vaccination guidelines for infants at risk for HIV infection", Weekly Epidemiological Record, Geneva: 2007:82(21):193–196.

73

World Health Organization (WHO). "Influenza Vaccines WHO Position Paper", Weekly Epidemiological Record, No. 33, 19 August 2005.

74

World Health Organization (WHO). Website (Vaccine-preventable diseases section). Available at: www.who.int/immunization_monitoring/diseases/MNTE_initiative (Accessed 19 May 2010).

75

World Health Organization (WHO). Website (Maternal and Neonatal Tetanus (MNT) elimination). Available at: www.who.int/immunization_monitoring/diseases/MNTE_initiative/en/index4.html (Accessed January 2012)

76

D. Baxter. (2007). Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond) 57 (8): 552–556. doi: 10.1093/occmed/kqm11.

77

World Health Organization (WHO). Website (Information related to influenza immunization). Available at: www.who.int/influenza/vaccines/SAGE_information (Accessed 25 May 2012).

78
79

WHO WER 2007; 82:17–24 and WER 2007; 82:181–96.

8

80

Siegrist CA, Lewis EM, Eskola J, Evans S, Black S. "Human Papilloma Virus Immunization in Adolescent and Young Adults: A Cohort Study to Illustrate What Events Might be Mistaken for Adverse Reactions." The Pediatric Infectious Disease Journal. Volume 26, Number 11, November 2007.